Hyaluronan synthase 2 (HAS2) overexpression diminishes the procatabolic activity of chondrocytes by a mechanism independent of extracellular hyaluronan

• Published in: The Journal of biological chemistry 2019-09, Vol.294 (37), p.13562-13579
• Main Authors: Ishizuka, Shinya, Tsuchiya, Saho, Ohashi, Yoshifumi, Terabe, Kenya, Askew, Emily B., Ishizuka, Naoko, Knudson, Cheryl B., Knudson, Warren
• Format: Article
• Language: English
• Subjects: aggrecan; Aggrecans - metabolism; Animals; cartilage catabolism; Cartilage, Articular - metabolism; Cattle; Cell Adhesion Molecules - metabolism; Cells, Cultured; chondrocyte; Chondrocytes - metabolism; Glycobiology and Extracellular Matrices; Humans; hyaluronan; hyaluronan synthase 2 (HAS2); Hyaluronan Synthases - biosynthesis; Hyaluronan Synthases - genetics; Hyaluronan Synthases - metabolism; Hyaluronic Acid - metabolism; inflammation; matrix metalloproteinase (MMP); Matrix Metalloproteinase 13 - metabolism; Matrix Metalloproteinase 3 - metabolism; metabolomics; Metabolomics - methods; osteoarthritis; Osteoarthritis - genetics; Osteoarthritis - metabolism; Primary Cell Culture
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.RA119.008567

Osteoarthritis (OA) is a progressive degenerative disease of the joints caused in part by a change in the phenotype of resident chondrocytes within affected joints. This altered phenotype, often termed proinflammatory or procatabolic, features enhanced production of endoproteinases and matrix metallo-proteinases (MMPs) as well as secretion of endogenous inflammatory mediators. Degradation and reduced retention of the proteoglycan aggrecan is an early event in OA. Enhanced turnover of hyaluronan (HA) is closely associated with changes in aggrecan. Here, to determine whether experimentally increased HA production promotes aggrecan retention and generates a positive feedback response, we overexpressed HA synthase-2 (HAS2) in chondrocytes via an inducible adenovirus construct (HA synthase-2 viral overexpression; HAS2-OE). HAS2-OE incrementally increased high-molecular-mass HA >100-fold within the cell-associated and growth medium pools. More importantly, our results indicated that the HAS2-OE expression system inhibits MMP3, MMP13, and other markers of the procatabolic phenotype (such as TNF-stimulated gene 6 protein (TSG6)) and also enhances aggrecan retention. These markers were inhibited in OA-associated chondrocytes and in chondrocytes activated by interleukin-1β (IL1β), but also chondrocytes activated by lipopolysaccharide (LPS), tumor necrosis factor α (TNFα), or HA oligosaccharides. However, the enhanced extracellular HA resulting from HAS2-OE did not reduce the procatabolic phenotype of neighboring nontransduced chondrocytes as we had expected. Rather, HA-mediated inhibition of the phenotype occurred only in transduced cells. In addition, high HA biosynthesis rates, especially in transduced procatabolic chondrocytes, resulted in marked changes in chondrocyte dependence on glycolysis versus oxidative phosphorylation for their metabolic energy needs.